Literature DB >> 25024359

Point/counterpoint: is there a role for radiotherapy in the treatment of primary CNS lymphoma?

Patrick Y Wen1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25024359      PMCID： PMC4096188          DOI： 10.1093/neuonc/nou135

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  5 in total

1.  Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

Authors:  Lisa M DeAngelis; Wendy Seiferheld; S Clifford Schold; Barbara Fisher; Christopher J Schultz
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

2.  MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years.

Authors:  Andrés J M Ferreri; Fabio Ciceri; Alba A Brandes; Mauro Montanari; Monica Balzarotti; Michele Spina; Fiorella Ilariucci; Francesco Zaja; Caterina Stelitano; Flavio Bobbio; Gaetano Corazzelli; Luca Baldini; Michele Reni
Journal:  Neurology       Date:  2014-03-14       Impact factor: 9.910

3.  High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

Authors:  Andrés J M Ferreri; Michele Reni; Marco Foppoli; Maurizio Martelli; Gerasimus A Pangalis; Maurizio Frezzato; Maria Giuseppina Cabras; Alberto Fabbri; Gaetano Corazzelli; Fiorella Ilariucci; Giuseppe Rossi; Riccardo Soffietti; Caterina Stelitano; Daniele Vallisa; Francesco Zaja; Lucía Zoppegno; Gian Marco Aondio; Giuseppe Avvisati; Monica Balzarotti; Alba A Brandes; José Fajardo; Henry Gomez; Attilio Guarini; Graziella Pinotti; Luigi Rigacci; Catrina Uhlmann; Piero Picozzi; Paolo Vezzulli; Maurilio Ponzoni; Emanuele Zucca; Federico Caligaris-Cappio; Franco Cavalli
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

4.  Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.

Authors:  Patrick G Morris; Denise D Correa; Joachim Yahalom; Jeffrey J Raizer; David Schiff; Barbara Grant; Sean Grimm; Rose K Lai; Anne S Reiner; Kathy Panageas; Sasan Karimi; Richard Curry; Gaurav Shah; Lauren E Abrey; Lisa M DeAngelis; Antonio Omuro
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

5.  Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

Authors:  James L Rubenstein; Eric D Hsi; Jeffrey L Johnson; Sin-Ho Jung; Megan O Nakashima; Barbara Grant; Bruce D Cheson; Lawrence D Kaplan
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544
  5 in total
  1 in total

1.  Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study.

Authors:  Yoko Nakasu; Koichi Mitsuya; Nakamasa Hayashi; Ikue Okamura; Keita Mori; Terukazu Enami; Raine Tatara; Satoshi Nakasu; Takashi Ikeda
Journal:  Springerplus       Date:  2016-03-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.